LEIDEN, NETHERLANDS--(Marketwire - November 06, 2007) -
OctoPlus N.V. ("OctoPlus") (Euronext: OCTO), the drug delivery and development company, announces that full and complete results from its successful SELECT-1 Phase IIa clinical trial of Locteron™ for the treatment of chronic hepatitis C will be presented today at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
